These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10876518)

  • 1. Alpha-2 agonists in the treatment of attention deficit hyperactivity disorder.
    Scahill L; Barloon L; Farkas L
    J Child Adolesc Psychiatr Nurs; 1999; 12(4):168-73. PubMed ID: 10876518
    [No Abstract]   [Full Text] [Related]  

  • 2. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder.
    Arnsten AF; Steere JC; Hunt RD
    Arch Gen Psychiatry; 1996 May; 53(5):448-55. PubMed ID: 8624188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylphenidate an effective treatment for ADHD?
    McDougle CJ
    J Autism Dev Disord; 2004 Oct; 34(5):593-4. PubMed ID: 15628613
    [No Abstract]   [Full Text] [Related]  

  • 4. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness.
    Scahill L
    CNS Drugs; 2009; 23 Suppl 1():43-9. PubMed ID: 19621977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms.
    Stahl SM
    J Clin Psychiatry; 2010 Mar; 71(3):223-4. PubMed ID: 20331927
    [No Abstract]   [Full Text] [Related]  

  • 6. In the pipeline: non-stimulant ADHD meds.
    Glazer WM
    Behav Healthc; 2010 Jan; 30(1):30-1. PubMed ID: 20184258
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
    Sallee FR
    Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data.
    Arnsten AF; Scahill L; Findling RL
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):393-406. PubMed ID: 17822336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children.
    Newcorn JH; Schulz K; Harrison M; DeBellis MD; Udarbe JK; Halperin JM
    Pediatr Clin North Am; 1998 Oct; 45(5):1099-22, viii. PubMed ID: 9884677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological management of attention-deficit hyperactivity disorder.
    Reeves G; Schweitzer J
    Expert Opin Pharmacother; 2004 Jun; 5(6):1313-20. PubMed ID: 15163276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychiatry; 2006; 67 Suppl 8():32-8. PubMed ID: 16961428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonidine for treatment of attention-deficit/hyperactivity disorder.
    Med Lett Drugs Ther; 1996 Dec; 38(989):109-10. PubMed ID: 8957471
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of hyperactivity in children with pervasive developmental disorders.
    Scahill L; Pachler M
    J Child Adolesc Psychiatr Nurs; 2007 Feb; 20(1):59-62. PubMed ID: 17284238
    [No Abstract]   [Full Text] [Related]  

  • 14. Introduction: new developments in the treatment of attention-deficit/hyperactivity disorder.
    Biederman J
    J Clin Psychiatry; 2006; 67 Suppl 8():4-6. PubMed ID: 16961423
    [No Abstract]   [Full Text] [Related]  

  • 15. Treating ADHD in Prison: Focus on Alpha-2 Agonists (Clonidine and Guanfacine).
    Mattes JA
    J Am Acad Psychiatry Law; 2016 Jun; 44(2):151-7. PubMed ID: 27236168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [α2-Adrenergic agonists, and drugs for ADHD].
    Clement HW; Schulz E
    Pharm Unserer Zeit; 2011 Nov; 40(6):503-9. PubMed ID: 22028136
    [No Abstract]   [Full Text] [Related]  

  • 17. Psychopharmacology for the clinician: management of comorbid Tourette syndrome and attention-deficit/hyperactivity disorder: are psychostimulants an option?
    Pringsheim T
    J Psychiatry Neurosci; 2012 Nov; 37(6):432. PubMed ID: 23092593
    [No Abstract]   [Full Text] [Related]  

  • 18. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
    Biederman J; Spencer T; Wilens T
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):77-97. PubMed ID: 14733627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newly approved once-daily formulations of medications for the treatment of Attention Deficit (Hyperactivity) Disorder (ADHD) in children and adolescents.
    Roman MW
    Issues Ment Health Nurs; 2010 Aug; 31(8):548-9. PubMed ID: 20624025
    [No Abstract]   [Full Text] [Related]  

  • 20. Stimulation of postsynapse adrenergic α2A receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder.
    Kawaura K; Karasawa J; Chaki S; Hikichi H
    Behav Brain Res; 2014 Aug; 270():349-56. PubMed ID: 24882610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.